Mechanism of action<unk>  inhibits "the contraction of isolated vascular smooth muscle, including that from the tumours of cancer patients. It also reduces the migration of some cancer and normal cells in culture." As a PARP inhibitor,<unk>  is expected to be more effective in the 9% of pancreatic cancers with a BRCA mutation (BRCA1 or BRCA2).
Rucaparib
Olaparib
Decitabine
Zalcitabine
Martinostat
Apricitabine
Trifluridine
Panobinostat